The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
KADMON HLDGS INC | COM | 48283N106 | 126 | 30,000 | SH | SOLE | 0 | 30,000 | 0 | ||
EKSO BIONICS HLDGS INC | COM | 282644301 | 2,192 | 774,400 | SH | SOLE | 0 | 774,400 | 0 | ||
BELLEROPHON THERAPEUTICS INC | COM NEW | 078771300 | 6,064 | 553,250 | SH | SOLE | 0 | 553,250 | 0 | ||
TRACON PHARMACEUTICALS INC | COM NEW | 89237H209 | 31 | 18,107 | SH | SOLE | 0 | 18,107 | 0 | ||
CORVUS PHARMACEUTICALS INC | COM | 221015100 | 80 | 38,010 | SH | SOLE | 0 | 38,010 | 0 | ||
SCYNEXIS INC | COM | 811292101 | 67 | 86,075 | SH | SOLE | 0 | 86,075 | 0 |